Journal of the American Chemical Society p. 2177 - 2194 (1991)
Update date:2022-07-30
Topics:
Denmark, Scott E.
Henke, Brad R.
Model compounds 1 and 2 have been studied to elucidate the relative orientation of enolate and carbonyl moieties in the aldol reaction. The syntheses of these compounds have been achieved from a common precursor derived from fragmentation of adamantane. Models of the limiting transition structures reveal that the cyclization must proceed through either a synclinal or antiperiplanar orientation of the aldehyde with respect to the enolate. Cyclizations of 1 were unexpectedly sluggish due to slow deprotonation of the tertiary center. The cyclization of 2 was very rapid and was studied as a function of enolate type (metal counterion), base type, solvent, and additive. The reactions of metal enolates showed an increasing preference for the syn product 5 with increasing cation coordinating ability (K+ < Na+ < Li+ < MgBr+). Attempted cyclization via boron and stannous enolates failed. The type of base and the choice of solvent had negligible effects on the selectivity. However, in the presence of strong cation-complexing agents, the model showed a strong preference for reaction via an antiperiplanar orientation of reactants giving the anti product 6 with high selectivity. The origin of the selectivities and the implication for enolate and transition structures are discussed.
View Morewebsite:http://www.antimex.com
Contact:0086-21-50563169
Address:Room1027,No.Jinyu Road,Pudong
Jiangsu Zenji Pharmaceuticals LTD
Contact:+86-025-83172562; +1-224-888-1133(USA)
Address:No.5 Xinmofan Road
Shanghai Sunwise Chemical Co., Ltd
website:http://www.sunwisechem.com
Contact:86-021-33883180
Address:Room 10E, Building G, Westlink Center, No. 2337 Gudai Road, Minhang District, Shanghai, China PC: 201100
Contact:(1) 206-3550089
Address:5115 NE 8TH PL, Renton, WA 98059 USA
NEW FORTUNE INDUSTRIAL CO.,LTD.
website:http://newfortune.lookchem.com/
Contact:+86-25-8645-9456
Address:C4-105 GREEN ISLAND FLOWER TOWN
Doi:10.1016/j.ijpharm.2011.06.007
(2011)Doi:10.1016/0040-4039(95)02130-2
(1996)Doi:10.1002/chem.201103809
(2012)Doi:10.1021/ol301739f
(2012)Doi:10.1002/anie.201201799
(2012)Doi:10.1039/c5sc03704b
(2016)